Welcome to our dedicated page for Opus Genetics SEC filings (Ticker: IRD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Opus Genetics, Inc.'s SEC filings document financing, governance, capital-structure and operating disclosures for a Delaware clinical-stage biopharmaceutical company developing ophthalmic gene therapies. Form 8-K reports cover senior secured notes, preferred stock private placement activity, financial results, corporate presentations and compensatory arrangements.
Proxy materials and stockholder-vote reports cover director elections, auditor ratification, say-on-pay matters and amendments affecting authorized common stock. The filings also record corporate updates related to the company's inherited retinal disease pipeline and Phentolamine Ophthalmic Solution 0.75%.
IRD submits a Form 144 notice reporting the proposed sale of 30,227 shares of Common Stock issued upon an RSU grant vest on 04/23/2026 with cash as the planned consideration. The filing also records a prior sale of 24,438 shares by George N. Magrath on 03/16/2026.
IRD filed a Form 144 notice reporting proposed sales and a recent RSU vesting. The filing records an RSU grant vest of 25,000 common shares dated 04/22/2026 with cash settlement on 04/23/2026. It also shows a prior sale of 3,719 common shares on 03/16/2026 with an associated amount of $19,046.00.
Rodgers Richard J reported acquisition or exercise transactions in this Form 4 filing.
Opus Genetics, Inc. director Richard J. Rodgers received an equity grant in the form of restricted stock units covering 24,367 shares of common stock. The award was granted at no cash cost per share and is part of his director compensation.
The restricted stock units vest upon the earlier of the one-year anniversary of the grant date or the day before Opus Genetics’ next annual stockholders’ meeting, provided he continues to serve through the vesting date. After this grant, he directly holds 343,022 shares of common stock.
MANUSO JAMES S J reported acquisition or exercise transactions in this Form 4 filing.
Opus Genetics, Inc. director JAMES S J MANUSO received a grant of 24,367 shares of Common Stock in the form of restricted stock units at a stated price of $0.00 per share. Following this award, he holds 317,318 shares directly. The RSUs vest upon the earlier of one year from the grant date or the day before the company’s next annual meeting of stockholders, provided he continues in service through the vesting date.
Graves Adrienne L reported acquisition or exercise transactions in this Form 4 filing.
Opus Genetics, Inc. director Adrienne L. Graves received a grant of 24,367 shares of Common Stock in the form of restricted stock units as compensation. These units vest upon the earlier of one year from the grant date or the day before the company’s next annual stockholder meeting, subject to continued service. After this award, Graves directly holds 127,514 shares of common stock.
Gallagher Cam reported acquisition or exercise transactions in this Form 4 filing.
Opus Genetics, Inc. director Cam Gallagher reported an equity compensation grant and updated share holdings. He received 24,367 shares of Common Stock as a grant of restricted stock units at $0.0000 per share, which vest upon the earlier of one year from grant or the day before the next annual stockholder meeting, subject to continued service. Following this grant, he directly holds 2,015,797 Common Stock shares. A separate holding entry shows 83,000 Common Stock shares held indirectly as custodian for a minor child under the Uniform Transfer to Minors Act, for which he disclaims beneficial ownership except to any pecuniary interest.
Benton Susan reported acquisition or exercise transactions in this Form 4 filing.
Opus Genetics, Inc. director Susan Benton received a grant of 24,367 restricted stock units of common stock as equity compensation. The units vest on the earlier of one year from the grant date or the day before the company’s next annual stockholder meeting, contingent on her continued service. After this grant, she directly holds 243,894 shares of common stock.
Opus Genetics, Inc. director Jean Bennett received a grant of 24,367 shares of Common Stock in the form of restricted stock units on April 20, 2026. The grant has no cash exercise price and represents equity compensation rather than an open-market purchase.
The restricted stock units vest upon the earlier of the one-year anniversary of the grant date or the day prior to Opus Genetics’ next annual meeting of stockholders, as long as Bennett continues in service through the vesting date. Following this grant, her direct holdings increased to 259,019 shares of Common Stock.